Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Completes Assays for Tacere, Pfizer RNAi Drug Alliance

Premium

Exiqon announced this week that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.

As reported by RNAi News early last year, Tacere licensed its preclinical hepatitis C therapy TT-033 to Pfizer worldwide except in Asia, where Oncolys BioPharma has the drug's rights (see RNAi News, 1/10/2008).

According to Exiqon, the assays will be used to "assess critical performance points for the RNAi therapeutic in a preclinical setting."

Specific terms of the arrangement with Tacere were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.